Prompt diagnosis and treatment of infantile epileptic spasms syndrome, a severe seizure disorder beginning in infancy, can prevent developmental delays. But non-Hispanic Black children are less likely ...

Infantile spasms represent a severe epileptic encephalopathy predominantly affecting early childhood, with West syndrome constituting a well‐defined clinical subset marked by a triad of spasms, ...

"Infantile spasms are a medical emergency and can cause permanent brain damage if not treated immediately," said Kari Luther Rosbeck, President & CEO of the TSC Alliance ®. "Infantile Spasms Awareness ...

New research from Tufts University School of Medicine and the Graduate School of Biomedical Sciences suggests that the timing of the death of certain inhibitory neurons in the brain shortly after ...

Infantile epileptic spasms syndrome (IESS), often called infantile spasms, is the most common form of epilepsy seen during infancy. Prompt diagnosis and referral to a neurologist are essential. But ...

Vigafyde is a concentrated solution and requires a smaller volume than other vigabatrin products to obtain the same dosage. The Food and Drug Administration (FDA) has approved Vigafyde ™, a ...

Healio spoke with Eric Kossoff, MD, about screening, diagnosing and treating infantile spasms. “Infantile spasms is a condition that we actually do see a fair bit of,” he said. “Although it’s ...

Infantile spasms, also known as West Syndrome in other geographies, is a severe, ultra-rare form of epilepsy that affects infants under the age of 36 months. Incidence is estimated at approximately ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, announced today that the U.S ...

Vigadrone ® (vigabatrin), an AB-rated generic version of Sabril ®, is now available as a 500mg tablet in addition to the powder for oral solution formulation (500mg packets containing a granular ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, announced today that ...